St. Jude Medical Inc. (NYSE:STJ) won CE Mark approval for its Athena deep-brain stimulation programmer, designed to help physicians control the amount of current delivered to patients’ brains to treat Parkinson’s disease.
The St. Paul, Minn.-based medical device maker said the latest iteration of the programmer also allows doctors to store up to 200,000 patient records. It’s designed to work with St. Jude’s Libra, LibraXP and Brio DBS systems, according to a press release.
There’s a DBS donnybrook brewing in the Twin Cities, as St. Jude and crosstown rival Medtronic Inc. (NYSE:MDT) battle for space in the market. Medtronic last week won CE Mark approval for its Activa DBS system for epilepsy. In March, St. Jude landed Australian approval for its BRIO device for Parkinson’s.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.